Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Radiation with or without Olaparib in Localized High-risk Prostate Cancer
NCT05568550Phase 2Recruiting
- Start
- Jul 2023
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, olaparib in prostate cancer (PCa). Started Jul 2023; status: recruiting.
02
Drugs
pembrolizumabolaparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05568550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05568550.